Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Correspondence] Mortality risk with dual antiplatelet therapy?

The dual antiplatelet therapy (DAPT) study1 identified a significant reduction in ischaemic cardiovascular events with prolonged thienopyridine use on a background of aspirin therapy. An unexpectedly high mortality rate was seen among patients treated with drug-eluting stents who were randomly allocated to receive continued thienopyridine compared with placebo (2·0% vs 1·5%, p=0·05). Because of the crucial role that these medications have in treatment of cardiovascular disease, these findings prompted appropriate attention.

email